First Quarter 2022 Highlights

• Revenue for the first quarter of 2022 was US$92.0 million, a record high, compared to US$57.5 million in the first quarter of 2021
• (Loss)/profit from operations under IFRS was US$(0.6) million in the first quarter of 2022, compared to US$11.1 million in the first quarter of 2021. Adjusted EBITDA (non-IFRS)[2] was US$12.7 million compared to US$12.5 million in the first quarter of 2021
• Potential acquisition targets being identified in the telehealth and personalized care sectors in Southeast Asia and in Europe
• Performed and delivered more than 22 million COVID-19 laboratory and rapid at-home tests globally to date
• Registration Statement for proposed business combination with Artisan Acquisition Corp. declared effective by the SEC, with Nasdaq listing expected on May 18, 2022, subject to satisfaction or waiver of the conditions